Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Incyte Corporation Incyte Announces Final Results of Tender Offer June 13, 2024 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces Preliminary Results of Tender Offer June 11, 2024 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock May 13, 2024 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa March 10, 2024 From Incyte Corporation Via Business Wire Tickers INCY Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs August 01, 2023 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo March 18, 2023 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo March 18, 2023 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023 March 14, 2023 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents February 24, 2023 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo March 14, 2022 From Incyte Corporation Via Business Wire Tickers INCY Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs February 08, 2022 From Incyte Corporation Via Business Wire Tickers INCY Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) July 23, 2021 From Incyte Corporation Via Business Wire Tickers INCY Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis June 11, 2021 From Incyte Corporation Via Business Wire Tickers INCY Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
